Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biomed Opt Express. 2013 Jan 1;4(1):105-21. doi: 10.1364/BOE.4.000105. Epub 2012 Dec 14.

Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.

Author information

  • 1Dept. of Physics and Astronomy, University of Pennsylvania, 209 S. 33rd St., Philadelphia, PA 19104 USA.

Abstract

We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancer signature for monitoring progression of neoadjuvant chemotherapy. This signature, called probability of malignancy, is obtained by statistical image analysis of total hemoglobin concentration, blood oxygen saturation, and scattering coefficient distributions in the breast tomograms of a training-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adapts this statistical image analysis approach for chemotherapy monitoring of three patients. Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes.

KEYWORDS:

(170.1610) Clinical applications; (170.3830) Mammography; (170.3880) Medical and biological imaging; (170.6510) Spectroscopy, tissue diagnostics

PMID:
23304651
[PubMed]
PMCID:
PMC3539198
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk